Technical Analysis for BOLT - Bolt Biotherapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.11 | 2.78% | 0.03 |
BOLT closed up 2.78 percent on Wednesday, May 8, 2024, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 200 DMA Resistance | Bearish | 2.78% | |
| Narrow Range Bar | Range Contraction | 2.78% | |
| 200 DMA Resistance | Bearish | 0.91% | |
| Narrow Range Bar | Range Contraction | 0.91% | |
| Inside Day | Range Contraction | 0.91% | |
| 200 DMA Resistance | Bearish | 0.91% | |
| Gapped Up | Strength | 0.91% |
| Alert | Time |
|---|---|
| Possible NR7 | about 13 hours ago |
| 200 DMA Resistance | about 14 hours ago |
| 60 Minute Opening Range Breakout | about 14 hours ago |
| Rose Above 200 DMA | about 14 hours ago |
| Up 2% | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Pharmaceutical Products Tumor Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Pharmaceutical Products Tumor Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.03 |
| 52 Week Low | 0.84 |
| Average Volume | 130,028 |
| 200-Day Moving Average | 1.11 |
| 50-Day Moving Average | 1.20 |
| 20-Day Moving Average | 1.13 |
| 10-Day Moving Average | 1.11 |
| Average True Range | 0.06 |
| RSI (14) | 44.44 |
| ADX | 17.44 |
| +DI | 13.33 |
| -DI | 20.70 |
| Chandelier Exit (Long, 3 ATRs) | 1.17 |
| Chandelier Exit (Short, 3 ATRs) | 1.22 |
| Upper Bollinger Bands | 1.22 |
| Lower Bollinger Band | 1.04 |
| Percent B (%b) | 0.38 |
| BandWidth | 15.64 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0024 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.14 | ||||
| Resistance 3 (R3) | 1.14 | 1.12 | 1.14 | ||
| Resistance 2 (R2) | 1.12 | 1.12 | 1.13 | 1.13 | |
| Resistance 1 (R1) | 1.12 | 1.11 | 1.12 | 1.12 | 1.13 |
| Pivot Point | 1.10 | 1.10 | 1.11 | 1.11 | 1.10 |
| Support 1 (S1) | 1.10 | 1.10 | 1.10 | 1.10 | 1.09 |
| Support 2 (S2) | 1.08 | 1.09 | 1.09 | 1.09 | |
| Support 3 (S3) | 1.08 | 1.08 | 1.09 | ||
| Support 4 (S4) | 1.08 |
